phrykt

UNITED THERAPEUTICS Corp (UTHR): who owns it and who trades it

As of Nov 16, 2026, UTHR insiders reported 2899 open-market sales worth $1.5B and 1 purchase worth $864K in the last 12 months, with 13% of the sale value made under pre-set 10b5-1 plans. The largest seller was Martine A Rothblatt (CEO), with $976M. 8 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling United Therapeutics

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns UTHR

877 funds and institutions reported UTHR shares worth $22.7B at the end of Q2 2026, about 99% of the company. The largest holder is BlackRock, Inc. with 12.5%.

Funds and institutions (13F) 99%Everyone else 1%

10 largest owners, by share of the company

BlackRock, Inc.12.5%
Avoro Capital Advisors LLC6.5%
Vanguard Portfolio Management LLC4.5%
Vanguard Capital Management LLC4.5%
State Street Corp4.5%
Renaissance Technologies LLC4.0%
Wellington Management Group LLP3.2%
Geode Capital Management, LLC2.3%
Jupiter Topco LLC2.0%
Norges Bank1.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.5.29M12.47%$2.9B-2%
Avoro Capital Advisors LLC2.78M6.54%$1.5B+6%
Vanguard Portfolio Management LLC1.92M4.52%$1B-4%
Vanguard Capital Management LLC1.92M4.52%$1B-2%
State Street Corp1.90M4.47%$1B+3%
Renaissance Technologies LLC1.71M4.03%$926M-4%
Wellington Management Group LLP1.38M3.25%$747M-39%
Geode Capital Management, LLC996,5982.35%$539M-19%
Jupiter Topco LLC831,1291.96%$450M–
Norges Bank694,7531.64%$376M–
Assetmark, Inc624,0681.47%$338M+1%
AQR Capital Management LLC546,0021.29%$295M-34%
Dimensional Fund Advisors LP527,9041.24%$286M+3%
FMR LLC (Fidelity)473,4091.12%$257M-10%
Invesco Ltd.473,1091.11%$256M-22%
Baillie Gifford & Co467,2091.10%$253M+9%
Deerfield Management Company, L.P.457,0001.08%$248MNo change
Morgan Stanley436,6991.03%$237M+7%
Vestal Point Capital, LP435,0001.02%$236M+480%
Northern Trust Corp430,8441.02%$233M-1%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, UTHR insiders reported $864K of open-market purchases and $1.5B of sales. 13% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$864K
1 trades, 1 people
Sales, 12 months
$1.5B
2899 trades, 12 people
Sales under a 10b5-1 plan
13%
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 16, 2026

Purchases and sales by month

$177M$177MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026Martine A RothblattCEOSale plan528$587.42$310KForm 4
Nov 13, 2026Martine A RothblattCEOSale plan493$588.61$290KForm 4
Nov 13, 2026Martine A RothblattCEOSale plan603$589.80$356KForm 4
Nov 13, 2026Martine A RothblattCEOSale plan1,657$590.65$979KForm 4
Nov 13, 2026Martine A RothblattCEOSale plan2,181$591.56$1.3MForm 4
Nov 13, 2026Martine A RothblattCEOSale plan518$592.61$307KForm 4
Nov 13, 2026Martine A RothblattCEOSale plan245$593.81$145KForm 4
Nov 13, 2026Martine A RothblattCEOSale plan1,275$594.65$758KForm 4
Nov 13, 2026Martine A RothblattCEOSale plan1,040$595.41$619KForm 4
Nov 13, 2026Martine A RothblattCEOSale plan480$596.65$286KForm 4
Nov 13, 2026Martine A RothblattCEOSale plan440$597.48$263KForm 4
Nov 13, 2026Martine A RothblattCEOSale plan40$598.83$24KForm 4
Nov 12, 2026Martine A RothblattCEOSale plan159$587.00$93.3KForm 4
Nov 12, 2026Martine A RothblattCEOSale plan323$588.30$190KForm 4
Nov 12, 2026Martine A RothblattCEOSale plan427$589.21$252KForm 4
Nov 12, 2026Martine A RothblattCEOSale plan359$590.11$212KForm 4
Nov 12, 2026Martine A RothblattCEOSale plan317$591.10$187KForm 4
Nov 12, 2026Martine A RothblattCEOSale plan551$592.32$326KForm 4
Nov 12, 2026Martine A RothblattCEOSale plan1,934$593.44$1.1MForm 4
Nov 12, 2026Martine A RothblattCEOSale plan3,079$594.24$1.8MForm 4
Nov 12, 2026Martine A RothblattCEOSale plan1,409$595.17$839KForm 4
Nov 12, 2026Martine A RothblattCEOSale plan662$596.22$395KForm 4
Nov 12, 2026Martine A RothblattCEOSale plan280$597.33$167KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan25$584.20$14.6KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan215$585.93$126KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan320$586.59$188KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan271$588.16$159KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan292$589.18$172KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan301$590.31$178KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan736$591.56$435KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan1,172$592.68$695KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan961$593.57$570KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan991$594.66$589KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan1,346$595.46$801KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan1,324$596.74$790KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan1,299$597.61$776KForm 4
Nov 11, 2026Martine A RothblattCEOSale plan247$598.63$148KForm 4
Nov 10, 2026Martine A RothblattCEOSale plan40$577.52$23.1KForm 4
Nov 10, 2026Martine A RothblattCEOSale plan880$580.40$511KForm 4
Nov 10, 2026Martine A RothblattCEOSale plan742$581.36$431KForm 4
Nov 10, 2026Martine A RothblattCEOSale plan618$582.42$360KForm 4
Nov 10, 2026Martine A RothblattCEOSale plan980$583.64$572KForm 4
Nov 10, 2026Martine A RothblattCEOSale plan328$584.76$192KForm 4
Nov 10, 2026Martine A RothblattCEOSale plan795$585.56$466KForm 4
Nov 10, 2026Martine A RothblattCEOSale plan937$586.66$550KForm 4
Nov 10, 2026Martine A RothblattCEOSale plan620$587.96$365KForm 4
Nov 10, 2026Martine A RothblattCEOSale plan360$589.15$212KForm 4
Nov 10, 2026Martine A RothblattCEOSale plan2,040$589.95$1.2MForm 4
Nov 10, 2026Martine A RothblattCEOSale plan960$590.95$567KForm 4
Nov 10, 2026Martine A RothblattCEOSale plan120$592.20$71.1KForm 4
Nov 10, 2026Martine A RothblattCEOSale plan80$592.93$47.4KForm 4
Nov 9, 2026Christopher PatuskyDirectorSale1,210$580.00$702KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan80$556.52$44.5KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan161$558.07$89.8KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan168$558.70$93.9KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan71$559.80$39.7KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan517$561.15$290KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan512$562.35$288KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan291$563.49$164KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan160$564.36$90.3KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan220$565.56$124KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan300$566.57$170KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan400$567.48$227KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan240$569.21$137KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan280$570.22$160KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan322$571.78$184KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan358$572.62$205KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan280$573.94$161KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan85$574.91$48.9KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan315$576.37$182KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan120$577.45$69.3KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan160$578.45$92.6KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan294$579.58$170KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan300$580.16$174KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan520$581.52$302KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan1,732$582.79$1MForm 4
Nov 9, 2026Martine A RothblattCEOSale plan494$583.80$288KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan840$584.70$491KForm 4
Nov 9, 2026Martine A RothblattCEOSale plan280$585.63$164KForm 4
Nov 6, 2026Martine A RothblattCEOSale plan109$560.79$61.1KForm 4
Nov 6, 2026Martine A RothblattCEOSale plan2,005$561.80$1.1MForm 4
Nov 6, 2026Martine A RothblattCEOSale plan1,136$562.87$639KForm 4
Nov 6, 2026Martine A RothblattCEOSale plan870$563.85$491KForm 4
Nov 6, 2026Martine A RothblattCEOSale plan1,776$564.99$1MForm 4
Nov 6, 2026Martine A RothblattCEOSale plan1,742$565.85$986KForm 4
Nov 6, 2026Martine A RothblattCEOSale plan1,021$566.83$579KForm 4
Nov 6, 2026Martine A RothblattCEOSale plan761$567.64$432KForm 4
Nov 6, 2026Martine A RothblattCEOSale plan80$568.68$45.5KForm 4
Nov 5, 2026Martine A RothblattCEOSale plan320$562.51$180KForm 4
Nov 5, 2026Martine A RothblattCEOSale plan520$563.98$293KForm 4
Nov 5, 2026Martine A RothblattCEOSale plan720$565.32$407KForm 4
Nov 5, 2026Martine A RothblattCEOSale plan462$566.59$262KForm 4
Nov 5, 2026Martine A RothblattCEOSale plan156$567.93$88.6KForm 4
Nov 5, 2026Martine A RothblattCEOSale plan280$568.86$159KForm 4
Nov 5, 2026Martine A RothblattCEOSale plan562$570.53$321KForm 4
Nov 5, 2026Martine A RothblattCEOSale plan585$571.67$334KForm 4
Nov 5, 2026Martine A RothblattCEOSale plan375$572.61$215KForm 4
Nov 5, 2026Martine A RothblattCEOSale plan320$573.93$184KForm 4
Nov 5, 2026Martine A RothblattCEOSale plan320$574.46$184KForm 4
Nov 5, 2026Martine A RothblattCEOSale plan221$576.17$127KForm 4

Latest 100 of 2900 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Martine A RothblattChairperson & CEO, Director$864K$976MNov 13, 2026
James EdgemondCFO AND TREASURER–$193MJun 22, 2026
Michael BenkowitzPRESIDENT AND COO–$159MFeb 23, 2026
Paul A MahonEVP & GENERAL COUNSEL–$109MNov 5, 2026
Christopher PatuskyDirector–$3.4MNov 9, 2026
Louis W SullivanDirector–$3MDec 22, 2025
Tommy G ThompsonDirector–$2.5MMar 26, 2026
Ray KurzweilDirector–$2.4MMar 4, 2026
Christopher CauseyDirector–$2.3MMar 30, 2026
Judy D. OlianDirector–$417KMar 23, 2026
Jan MalcolmDirector–$373KJul 10, 2026
Nilda MesaDirector–$356KSep 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

UTHR short interest

Low short interest. 4.3% of UTHR shares are sold short: about 1 share in 23. Over the last 12 reports the number of shares short went down 20%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.84M UTHR shares were sold short, 4.3% of the shares outstanding, down 25.2% from the report before. At the average daily volume of 532,166 shares, buying them all back would take about 3.5 trading days (days to cover).

Shares short, % of all shares

4.31%May 15Oct 309.00%

Days to cover

3.5May 15Oct 306.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.84M4.31%-25%532,1663.5
Oct 15, 20262.46M5.73%-32%957,6702.6
Sep 30, 20263.60M8.39%+28%995,6213.6
Sep 15, 20262.80M6.53%+36%717,3033.9
Aug 31, 20262.06M4.80%-2%428,3394.8
Aug 14, 20262.11M4.93%-9%599,8413.5
Jul 31, 20262.32M5.42%+11%420,4295.5
Jul 15, 20262.09M4.92%-1%378,6015.5
Jun 30, 20262.12M4.99%+3%727,5042.9
Jun 15, 20262.05M4.84%-6%442,8444.6
May 29, 20262.19M5.16%-5%484,8854.5
May 15, 20262.30M5.43%-6%463,5805.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded UTHR

Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 2 sales of UTHR. The latest was a sale by Lisa C. McClain on Oct 31, 2025, reported Nov 21, 2025.

Purchases 2Sales 2

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Oct 31, 2025Lisa C. McClain (R-MI)Sale$1K–$15KSpouseNov 21, 2025Report
Oct 30, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseNov 21, 2025Report
Oct 30, 2025Lisa C. McClain (R-MI)Sale$1K–$15KSpouseNov 21, 2025Report
Jun 11, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseAug 13, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

United Therapeutics company events

United Therapeutics filed 13 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Oct 22, 2026AnnouncementThe Board of Directors of United Therapeutics Corporation (the Company ) approved a share repurchase program (the Share Repurchase Program ), authorizing the purchase by the Company of up to $2.0 billion of the Company’s common stock. Filing
  3. Oct 14, 2026AnnouncementUnited Therapeutics Corporation ( UT ) entered into a Settlement Agreement (the Settlement Agreement ) with Liquidia Technologies, Inc. ( Liquidia ) that provides for the resolution of pending litigation between the parties, as noted below: · UT v. Filing
  4. Sep 8, 2026AgreementUnited Therapeutics Corporation (the Company ) entered into an accelerated share repurchase agreement (the ASR Agreement ) with Citibank, N.A. ( Citi ) to repurchase approximately $477.6 million in the aggregate of the Company’s common stock ( Common Stock ) under the Company’s previously announced… Filing
  5. Aug 5, 2026ResultsReleased financial results. Filing
  6. Jul 23, 2026LeadershipThe Board of Directors (the Board ) of United Therapeutics Corporation (the Company ), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Victor Dzau, M.D., to serve as a member of the Board. Filing
  7. Jun 29, 2026LeadershipAs described in Item 5.07 below, on June 26, 2026, at the 2026 Annual Meeting of Shareholders of United Therapeutics Corporation (the Company ), the Company’s shareholders approved the United Therapeutics Corporation 2026 Stock Incentive Plan (the 2026 Plan ). Filing
  8. May 6, 2026ResultsReleased financial results. Filing
  9. Mar 30, 2026AnnouncementUnited Therapeutics Corporation issued a press release announcing positive results of the TETON-1 clinical study of Tyvaso ® (treprostinil) Inhalation Solution in patients with idiopathic pulmonary fibrosis. Filing
  10. Mar 9, 2026AgreementThe Board of Directors (the Board ) of United Therapeutics Corporation (the Company ) approved a share repurchase program (the Share Repurchase Program ), authorizing the purchase by the Company of up to $2.0 billion of the Company’s common stock ( Common Stock ) before March 9, 2027. Filing
  11. Mar 2, 2026AnnouncementShared information with investors. Filing
  12. Feb 25, 2026ResultsReleased financial results. Filing
  13. Jan 22, 2026LeadershipThe Board of Directors of United Therapeutics Corporation, acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Kevin J. Tracey, M.D., to serve as a member of the Board. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

United Therapeutics financials

Famous investors that hold UTHR

8 of the 50 well-known investors we track reported holding UTHR in their latest 13F filing. The largest position is Jim Simons's, worth $908M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.68M$908M1.2%-2%
Ken Griffin · Citadel AdvisorsQ3 2026928,464$503M0.3%+205%
Israel Englander · Millennium ManagementQ3 2026297,424$161M0.1%-27%
Steve Cohen · Point72 Asset ManagementQ3 2026176,950$95.9M0.2%-12%
Ray Dalio · Bridgewater AssociatesQ3 2026125,394$67.9M0.3%+13%
Ken Fisher · Fisher Asset ManagementQ3 202638,973$21.1M0.0%+15%
Jeremy Grantham · GMOQ3 20263,726$2M0.0%+14%
Lee Ainslie · Maverick CapitalQ3 20261,219$661K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named UTHR in the last 120 days.

FiledHolderFormStake
Nov 4, 2026Martine A. Rothblatt13G/A4.0%
Nov 4, 2026Martine A. Rothblatt13G/A4.0%

Questions about UNITED THERAPEUTICS Corp (UTHR) stock

Who owns the most UTHR stock?

The largest reported owner of UNITED THERAPEUTICS Corp (UTHR) is BlackRock, Inc., with 12.5% of the company. In total, 877 funds and institutions reported holding UTHR at the end of Q2 2026, together about 99% of the shares. See the largest owners.

Are UTHR insiders buying or selling?

In the last 12 months, UTHR insiders reported 1 open-market purchase worth $864K and 2,899 sales worth $1.5B. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in UTHR?

As of Oct 30, 2026, 1.84M UTHR shares were sold short, 4.3% of the shares outstanding, down 25.2% from the report before. At the average daily volume of 532,166 shares, buying them all back would take about 3.5 trading days (days to cover). See the history.

Have members of Congress traded UTHR?

Yes. 1 member of Congress reported 2 purchases and 2 sales of UTHR since Nov 17, 2024. The latest was reported on Nov 21, 2025. See the trades.

Which famous investors hold UTHR?

8 of the 50 well-known investors we track reported UTHR in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $908M. See all holders.

Executive pay

United Therapeutics's chief executive was paid a total of $18M for the year ended Dec 31, 2025, down 22% from $23M the year before. In the last 12 months, United Therapeutics's executives and directors bought $864K of stock on the open market and sold $1.5B.

Chief executive, total pay$18MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$150MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$9.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.